Skip to main content
. 2018 Jan 30;39(4):413–422. doi: 10.1093/asj/sjy019

Figure 2.

Figure 2.

Representative photographs of a 29-year-old female subject's lips and perioral area at (A) baseline, (B) 3 months, and (C) 1 year after treatment, and at 1 month after repeat treatment (D) with VYC-15L. She received initial treatment with 0.9 and 0.65 mL in the upper and lower lips, respectively, and touch-up treatment with 0.6 and 0.4 mL in the upper and lower lips, respectively. At repeat treatment, she received 0.85 and 0.75 mL in the upper and lower lips, respectively. (A) LFS at Baseline = Moderate; (B) LFS at Month 3 = Marked; (C) LFS at Month 12 = Moderate; (D) LFS at Month 1R = Marked. LFS, Allergan Lip Fullness Scale; Month 1R, Month 1 after repeat treatment; VYC-15L, Juvéderm Volbella XC.